A Meta-analysis of rh-endostatin Combined with Chemotherapy in the Treatment of Advanced Breast Cancer

Feng Lin Sen; Li Jing Juan; Wang Yu Feng

Article Contents

Article Navigation > Journal of Kunming Medical University > 2017 > 38(06): 118-123

Feng Lin Sen , Li Jing Juan , Wang Yu Feng . A Meta-analysis of rh-endostatin Combined with Chemotherapy in the Treatment of Advanced Breast Cancer[J]. Journal of Kunming Medical University, 2017, 38(06): 118-123.

Citation:

Feng Lin Sen , Li Jing Juan , Wang Yu Feng . A Meta-analysis of rh-endostatin Combined with Chemotherapy in the Treatment of Advanced Breast Cancer[J]. Journal of Kunming Medical University, 2017, 38(06): 118-123.

Citation:

PDF( 1141 KB)

A Meta-analysis of rh-endostatin Combined with Chemotherapy in the Treatment of Advanced Breast Cancer

Funds:

基金：中国临床肿瘤学会科研基金资助项目 (Y-S2016-002); 云南省教育厅科学研究基金重点资助项目 (2015Z089);

Received Date: 2017-02-13

Abstract

Abstract

Objective To evaluate the clinical efficacy and adverse effects induced by rh-endostatin (rh-ES) combined with chemotherapy in the treatment of advanced breast cancer. Methods The Pubmed, Embase, Cochrane Library, Spriner, CNKI, VIP, Wangfang Data, CBM were searched for literature up to April 2016. We searched randomized controlled clinical trials of rh-endostatin combined with chemotherapy in the treatment of advanced breast cancer and judged whether the trials met the inclusive criteria. Then Meta analysis was performed by using Rev Man v5.3 software after extracting useful data. Re s ults Six researches with 346 patients were included according to the inclusive criteria. Meta analysis demonstrated that rh-endostatin combined with chemotherapy had statistically significant increase over chemotherapy alone in terms of objective respond rate (RR=1.41, 95% CI: 1.13-1.77) or disease control rate (RR=1.21, 95% CI: 1.08-1.35) , and had statistically significant benefit in progression of disease ( RR=0.49, 95% CI: 0.32-0.75) . The incidence rates of leukopenia, thrombocytopenia and gastrointestinal reaction were no significant difference between two groups.Conclus ions Rh-endostatin combined with chemotherapy may have more meaningful clinical improvement in objective respond rate, disease control rate and progression of disease. The combination therapy had not added the adverse effects rates significantly.
- Breast neoplasms,
- Rh-endostatin,
- Clinical efficacy,
- Adverse effects,
- Meta analysis

FullText(HTML)

References(22)

References

[1]	[1]JAIN R K.Normalizing tumor microenvironment to treat cancer:bench to bedside to biomarkers[J].J Clin Oncol, 2013, 31 (17) :2205-18.
[2]	[2]HU B, ZHU H W, ZHU L P et al.Bioactivity, pharmacokinetics, and immunogenicity assays in preclinical and clinical trials for recombinant human endostatin[J].Acta Pharmacol Sin, 2008, 29 (11) :1357-69.
[3]	[3]PENG F, XU Z, WANG J, et al.Recombinant human endostatin normalizes tumor vasculature and enhances radiation response in xenografted human nasopharyngeal carcinoma models[J].PLo S One, 2012, 7 (4) :e34646.
[4]	[4]XU X, MAO W, CHEN Q et al.Endostar, a modified recombinant human endostatin, suppresses angiogenesis through inhibition of Wnt/beta-catenin signaling pathway[J].PLo S One, 2014, 9 (9) :e107463.
[5]	[5]MA X, YAO Y, YUAN D, et al.Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice[J].PLo S One, 2012, 7 (12) :e53449.
[6]	[6]GUO Z Y, YAO G D, FU L P, et al.Effect of recombinant human endostatin on the expression of c-Myc and b FGF in mouse gastric cancer cells[J].Genet Mol Res, 2015, 14 (2) :5258-65.
[7]王金万, 孙燕, 刘永煜, 等.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志, 2005, 8 (4) :283-290.
[8]	[8]CHEN J, YAO Q, LI D et al.Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer:efficacy and safety in a prospective, randomized, phase II study[J].BMC Cancer, 2013, 13 (1) :248.
[9]陈俊民, 谢贤和, 刘华, 等.GN方案联合抗血管生成疗法治疗蒽环类及紫杉类治疗失败的晚期乳腺癌的临床研究[J].现代预防医学, 2010, 37 (14) :2767-2769.
[10]陆颖, 黄海欣, 李桂生.血管内皮抑素联合GP方案治疗转移性三阴性乳腺癌的临床研究[J].中国肿瘤临床, 2012, 39 (23) :1946-1948+1955.
[11]徐春凌, 梁栋.GP方案联合恩度治疗晚期转移性乳腺癌的临床疗效[J].中国实用医药, 2012, 7 (23) :131-132.
[12]夏欣欣, 韩黎丽, 李晓阳, 等.重组人血管内皮抑制素联合化疗治疗晚期乳腺癌疗效观察[J].中华实用诊断与治疗杂志, 2014, 28 (6) :621-622.
[13]张宁玲, 李秋梅.重组人血管内皮抑素联合吉西他滨顺铂方案治疗转移性三阴性乳腺癌的疗效观察[J].中国肿瘤临床与康复, 2014, 21 (4) :436-439.
[14]孙艳丽, 陈武, 陈飞.重组人血管内皮抑素联合化疗对晚期乳腺癌循环血管内皮细胞和血管内皮细胞生长因子的影响[J].中国医师杂志, 2015, 17 (5) :735-737.
[15]谷鸿秋, 王杨, 李卫.Cochrane偏倚风险评估工具在随机对照研究Meta分析中的应用[J].中国循环杂志, 2014, 29 (2) :147-148.
[16]曹德东, 戈伟, 王慧敏, 等.重组人血管内皮抑素联合化疗与单纯化疗在晚期非小细胞肺癌中疗效比较的系统评价[J].中国肺癌杂志, 2011, 14 (5) :404-413.
[17]侯晓雯, 时景璞, 陈欣.在Meta分析中如何利用中位数、极差和样本量估算均数、标准差[J].中国循证医学杂志, 2015, 15 (4) :484-487.
[18]周支瑞, 张天嵩, 李博, 等.生存曲线中Meta分析适宜数据的提取与转换[J].中国循证心血管医学杂志, 2014, 3 (1) :243-247.
[19]中国抗癌协会乳腺癌专业委员会.复发转移乳腺癌化学治疗基本原则[J].中华医学杂志, 2011, 91 (2) :73-75.
[20]覃晶, 张鹏海, 钱新宇, 等.重组人血管内皮抑素联合化疗心脏毒性的分析[J].中国肿瘤临床, 2008, 35 (1) :12-14.
[21]	[21]RONG B, YANG S, LI W, et al.Systematic review and meta-analysis of endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer[J].World J Surg Oncol, 2012, 10 (1) :170.
[22]余婷婷, 徐细明, 陈彪.恩度联合GP方案治疗晚期非小细胞肺癌疗效及安全性的Meta分析[J].中华临床医师杂志 (电子版) , 2013, 7 (9) :3943-3946.

Relative Articles(20)

Relative Articles

[1]	Liyuan YUN, Junfeng WANG, Ning GUO, Ruimei DING, Haipeng LI, Xueping ZHANG. Analysis of the Efficacy and Safety of GM1 Injection Combined with Batroxobin in the Treatment of Sudden Deafness Patients. Journal of Kunming Medical University, 2024, 45(6): 140-144. doi: 10.12259/j.issn.2095-610X.S20240619
[2]	Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411
[3]	Qingmei YU, Tao SHI, Hongxue GUAN, Yujun MAO, Zhaoyi LI, Jiao YANG. Prevalence and Influence Factors of Renal Function Impairment in Patients Following Radical Cystectomy：A Systematic Review and Meta-analysis. Journal of Kunming Medical University, 2024, 45(9): 83-90. doi: 10.12259/j.issn.2095-610X.S20240913
[4]	Caini ZHANG, Ya LI. A Meta-analysis of the Efficacy and Safety of Camrelizumab Combined with Chemotherapy in the Treatment of Non-small Cell Lung Cancer. Journal of Kunming Medical University, 2024, 45(6): 75-84. doi: 10.12259/j.issn.2095-610X.S20240610
[5]	Xing LIU, Weixian LI, Yan WU, Xuejiao WU, Xiaodie YAO, Jie CHEN, Lingjun SHEN, Hao FAN. Efficacy and Safety of Jingangteng Capsules Combined with Antimicrobial Drugs in the Treatment of Chronic Pelvic Inflammatory Disease: A Meta-analysis. Journal of Kunming Medical University, 2024, 45(4): 81-91. doi: 10.12259/j.issn.2095-610X.S20240412
[6]	Keyan WANG, Bingting LIN, Xiaolin WENG, Bin HUANG, Lie WANG. Effectiveness and Safety Analysis of Cyclopol Combined with Remifentanil in Anesthesia for Endoscopic Gastric Cancer Radical Surgery. Journal of Kunming Medical University, 2024, 45(6): 154-160. doi: 10.12259/j.issn.2095-610X.S20240621
[7]	Jianmei LI, Yanling JIN. Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma. Journal of Kunming Medical University, 2023, 44(6): 120-125. doi: 10.12259/j.issn.2095-610X.S20230610
[8]	Yun-yan LAN, Yu-ran FENG, Yu ZHENG, Zhen-dong YANG, Yi ZHAO, Mei ZHU. Effectiveness of Low Intensity Focused Ultrasound Stimulation of Nucleus Accumbens in Mice. Journal of Kunming Medical University, 2021, 42(7): 13-19. doi: 10.12259/j.issn.2095-610X.S20210703
[9]	Lu Jiang Kun , Yuan Shao Feng , Pan Liang Ming , Wu Ming , Kong Xiang Dong . . Journal of Kunming Medical University, 2017, 38(03): 83-86.
[10]	Pan Zi Peng . Analysis and Safety Evaluation of the Clinical Efficacy of Laparoscopic Appendectomy for Acute Appendicitis. Journal of Kunming Medical University,
[11]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[12]	Zhang Wei . Meta Analysis of ADAM33 T1，S2 Polymorphism and the Susceptibility of Bronchial Asthma in China. Journal of Kunming Medical University,
[13]	Zeng Hai Ping . . Journal of Kunming Medical University,
[14]	Ke Zi Li . . Journal of Kunming Medical University,
[15]	Li Kai . . Journal of Kunming Medical University,
[16]	Li Gui Ling . . Journal of Kunming Medical University,
[17]	Li Gui Ling . . Journal of Kunming Medical University,
[18]	Zhou Jie . . Journal of Kunming Medical University,
[19]	Yan Jin . . Journal of Kunming Medical University,
[20]	. Efficacy and Safety of Extra-Care Soft Contact Lenses in Clinical Application. Journal of Kunming Medical University,